ABSTRACT Bacteriophages are viruses that kill bacteria. They are plentiful in nature with no known activity in human or animal cells, making them an attractive alternative to antibiotics. The objective of this research was to determine if a coarse or a fine spray of bacteriophage would prevent colibacillosis induced by an intratracheal (IT) challenge with Escherichia coli. Two studies were conducted with 6 treatments: untreated control, birds treated with a spray administration of bacteriophage and not challenged, birds administered bacteriophage IT and not challenged, birds not treated and challenged IT with E. coli, birds sprayed with bacteriophage and IT challenged with E. coli, and birds administered bacteriophage IT and challenged IT with E. coli. There were 3 replicate pens of 10 birds per pen, per treatment, and all treatments were administered at 1 d of age. Study 1 was concluded when the birds were 19 d of age, and study 2 was concluded when the birds were 21 d of age. In both studies, neither a coarse nor a fine spray protected the birds from an IT E. coli challenge; however, when bacteriophage was administered IT there was complete protection. This research demonstrates the necessity for the administration of bacteriophage therapeutics to deliver high bacteriophage titers to the site of a bacterial infection.
INTRODUCTION
Bacteriophages are viruses that kill bacteria. They have no known activity against plant and animal cells and are plentiful in nature, which makes them an attractive alternative to antibiotics. Bacteriophages were independently discovered by Twort (1915) and d 'Herelle (1917) . Research on the efficacy of bacteriophage to provide an alternative to antibiotics has increased as the need to find nonantibiotic approaches to prevent and treat bacterial disease has become increasingly important due to the emergence of antibiotic resistance and the pressure to decrease the use of antibiotics in animal production. Bacteriophage therapy has been shown to have efficacy to treat many diseases of plants, animals, and humans (Kutter and Sulakvelidze, 2005) . One of the first studies on the efficacy of bacteriophage to treat diseases was to prevent fowl typhus (d 'Herelle, 1926) . Our research has demonstrated that bacteriophages can be used to both prevent and treat colibacillosis in poultry (Huff et al., 2002a (Huff et al., ,b, 2003a . Furthermore, Miller et al. (2010) demonstrated the efficacy of bacteriophages to control necrotic enteritis. However, for bacteriophage therapy to be commercially successful in poultry production, the administration of bacteriophage must be practical within the poultry production system. We have not been able to show any efficacy of bacteriophage therapy for colibacillosis when bacteriophages were administered in the drinking water and the birds challenged via the air sac with Escherichia coli (Huff et al., 2002b) . One possible practical method to administer bacteriophages would be to incorporate bacteriophages into the spray vaccination system in the hatchery. This method of administration of bacteriophage could reduce the infectious dose of E. coli, providing protection to the juvenile bird until the bird's immune system matures. The objective of this research was to determine if a coarse or fine spray of birds at 1 d of age could protect the birds from developing colibacillosis when challenged intratracheally (IT) with E. coli.
MATERIALS AND METHODS

Bacteriophage Isolation and Amplification
Bacteriophage designated SPR02 was used in these studies, which was originally isolated from a municipal sewer treatment plant as described by Huff et al. (2002b) . The bacteriophage was amplified and numerated by procedures previously detailed (Huff et al., 2002b) . Briefly, a 2.5 h culture of E. coli was challenged with bacteriophage SPR02, incubated at 37°C under constant shaking, centrifuged to remove bacterial debris, and filter sterilized. This bacteriophage lysate was enumerated using a soft agar overlay procedure previously described (Huff et al., 2002b ).
E. coli Challenge Culture
The E. coli strain used in these studies was serotype 02, nonmotile, and lactose negative and was initially isolated from blood of chickens with colisepticemia (Bayyari et al., 1997; Huff et al., 1998) . The E. coli culture was prepared by inoculation of tryptose phosphate broth (Sigma Chemical Co., St. Louis, MO) that was incubated at 37°C in a shaking water bath for 2.5 h. The culture was removed from the water bath and held at 4°C. The culture was enumerated by making duplicate 10-fold serial dilutions of the culture and duplicate spread plating the appropriate dilutions on tryptose phosphate agar plates, which were enumerated after overnight incubation at 37°C. The challenge cultures were made by diluting this E. coli stock culture, and verified with serial dilutions of the challenge culture and enumeration by spread plating.
Experimental Design
In both studies, male broiler chicks (Cobb 500) were obtained at 1 d of age from a local hatchery and maintained in electrically heated batteries with feed and water available for ad libitum consumption. There were 6 treatments and 3 replicate pens of 10 birds for each treatment. The treatments consisted of 1) not treated and not challenged control, 2) birds sprayed with bacteriophage and not challenged, 3) birds administered IT bacteriophage and not challenged, 4) birds not treated and IT challenged with E. coli, 5) birds sprayed with bacteriophage and IT challenged with E. coli, and 6) birds IT administered bacteriophage and IT challenged with E. coli. In both studies, the birds were treated with bacteriophage and then immediately challenged with E. coli at 1 d of age. In study 1, a handheld garden-type spray bottle was used to administer the bacteriophage as a coarse spray, which was calibrated to deliver approximately 1 mL of a bacteriophage stock solution containing 3.9 × 10 9 pfu of bacteriophage sprayed on the bird's face. The IT administration of bacteriophage in study 1 was with 0.1 mL of the same stock solution of bacteriophage delivering 3.9 × 10 8 pfu per bird. In study 1, the birds were challenged IT with 0.1 mL of a stock solution of E. coli containing 2.1 × 10 8 cfu, providing a dose of 2.1 × 10 7 cfu. In study 2, a fine spray was generated using a model S-3 atomizing sprayer (Atomizing Systems Inc., Ho-Ho-Kus, NJ) with a model SN 30609-3 nozzle (Delavan Spray Technologies, Monroe, NC). It was thought that by decreasing the droplet size the fine spray would penetrate the respiratory tract deeper than the coarse spray. The spray was applied to the bird's face, delivering approximately 1 mL of a stock solution of bacteriophage containing 7 × 10 9 pfu. The IT administration of bacteriophage in study 2 was with 0.1 mL of the same bacteriophage stock solution providing 7 × 10 8 pfu. In study 2, the birds were IT challenged with 0.1 mL of a stock solution of E. coli containing 1.46 × 10 9 cfu providing a challenge dose of 1.46 × 10 8 cfu per bird. Intratracheal administrations were performed using a model IA-1B microspray aerosolizer (PennCentury Inc., Philadelphia, PA) Study 1 was concluded when the birds were 19 d of age and the birds were individually weighed at 7, 13, and 19 d of age. Study 2 was concluded when the birds were 21 d of age, and the birds were individually weighed weekly. Any bird that died during these studies was weighed, the severity of airsaculitis was scored (Huff et al., 1998) , and the liver and air sac were cultured with sterile transport swabs and plated on MacConkey's agar (Remel, Lenexa, KS). The liver, heart, spleen, and bursa of Fabricius were excised and weighed. At the conclusion of these studies the birds were humanely killed by cervical dislocation, and necropsied as described for the mortalities. All procedures described in these studies were approved by the University of Arkansas Animal Care and Use Committee.
Statistical Analysis
These data were analyzed by ANOVA (Snedecor and Cochran, 1967) , using the GLM procedures of SAS software (SAS Institute Inc., Cary, NC). All data presented as percentages were transformed as the square root of the arc sine before statistical analysis. Pen means were the unit for statistical analysis. Significant differences between treatments were separated using Duncan's multiple range test (Duncan, 1955) . All statements of significance are based on the probability level of ≤0.05.
RESULTS
In both studies, BW of the birds untreated and IT challenged with E. coli (treatment 4) and birds treated with either a coarse or fine spray of bacteriophage and IT challenged with E. coli (treatment 5) were significantly decreased compared with all other treatments that did not significantly differ from each other (data not shown). Necropsy results of birds that died were consistent with colibacillosis lesions characterized by airsacculitis and pericarditis; an increase in the relative 931 TREATMENT OF ESCHERICHIA COLI WITH BACTERIOPHAGE weights of the liver, spleen, and heart; and a decrease in the relative weight of the bursa of Fabricius (data not shown). Our challenge strain of E. coli was isolated from swabs of the air sac and liver in affected birds with over 90% of the cultures being pure, and swabs taken from our control birds were culture negative (data not shown). The challenge culture of E. coli is a lactosenegative, nonmotile, serotype 02 that is easily identified on MacConkey agar on the basis of fermentation of lactose and colony morphology.
The effect of these treatments on mortality is presented for study 1 and study 2 in Figures 1 and 2 , respectively. The trend for both studies was almost identical with significantly higher mortality noted in the birds untreated and IT E. coli challenged (treatment 4) and the birds sprayed with bacteriophage and IT E. coli challenged (treatment 5) than all other treatments, with the exception of study 1 (Figure 1) , where treatment 4 was not significantly different than the birds administered IT bacteriophage and unchallenged (treatment 3). Clearly the birds were protected from the onset of colibacillosis when treated with an IT administration of bacteriophage and IT challenge with E. coli (treatment 6), where mortality was not significantly different from the 3 control groups (treatments 1, 2, and 3) in both studies.
DISCUSSION
The current research demonstrates both the efficacy of bacteriophage therapy as well as the limitations of bacteriophage therapy. Throughout our research on the ability of bacteriophage to provide an alternative to antibiotics, one thing that appears to be true is that if sufficient titers of bacteriophage reach the site of a bacterial infection, bacteriophage therapy can be very effective (Huff et al., 2002a (Huff et al., ,b, 2003a (Huff et al., ,b, 2006 . However, there are constraints within the poultry production system that make the administration of bacteriophage to the birds to reduce the impact of colibacillosis on the poultry industry difficult. In the current research, neither a coarse nor a fine spray was able to prevent the onset of colibacillosis when the birds were challenged IT. Yet when bacteriophage and E. coli were both administered IT, complete protection from the onset of colibacillosis was evident. The failure of the coarse and fine spray when compared with the success of the IT administration of bacteriophage to prevent the onset of colibacillosis suggests that the neither the coarse nor fine spray was able to deliver sufficient titers of bacteriophage to the trachea to prevent the onset of colibacillosis. The current research clearly demonstrates the efficacy of bacteriophage to prevent infection when sufficient titers of bacteriophage can be delivered to the site of infection, and why bacteriophage therapy can fail when this is not achieved. Our research also demonstrated the importance of administration of bacteriophage with the inability to achieve therapeutic titers of bacteriophage with oral administration of bacteriophage to prevent colibacillosis (Huff et al., 2002b) . In addition, the importance of the method to deliver bacteriophage therapeutics can also be seen by comparing the current bacteriophage spray research with our previously reported bacteriophage research (Huff et al., 2002a) . In the previous work, we sprayed the birds with a fine spray within a chamber creating a mist and kept Figure 1 . Study 1. The effects of these treatments on mortality at 19 d of age. The treatments were 1) not treated and not challenged control; 2) birds treated with a coarse spray of bacteriophage and not challenged; 3) birds administered intratracheal (IT) bacteriophage and not challenged; 4) birds not treated and challenged with Escherichia coli; 5) birds treated with a coarse spray of bacteriophage and IT challenged with E. coli; and 6) birds treated IT with bacteriophage and challenged IT with E. coli. The values represent the means of 3 replicate pens of 10 birds per pen at each treatment, and the letters (a-c) indicate significant differences between treatment means (P ≤ 0.05).
them in the chamber for 3 min and were able to prevent the onset of colibacillosis when challenged with E. coli via the air sac. The previous research would have allowed the bacteriophage to penetrate the respiratory tract to a greater extent than just briefly spraying the birds as was done in the current research and probably explains the different results obtained in the current research. Furthermore, our research on the efficacy of bacteriophage to treat colibacillosis also demonstrates the importance of how bacteriophage therapeutics are delivered (Huff et al., 2003b) . The etiology of colibacillosis is that it starts as a respiratory infection that quickly becomes a systemic infection. In this work (Huff et al., 2003b) , an aerosol spray of bacteriophage was not an effective treatment, whereas an IM injection was very efficacious. This was due to the fact that we could get high titers of bacteriophages in the respiratory tract with a spray but not in the blood, whereas an IM injection produced high bacteriophage titers in the blood, allowing the bacteriophage to eliminate the systemic infection.
The potential of bacteriophage to prevent and treat bacterial diseases in poultry is significant. This potential cannot be realized unless practical and effective methods of administration of bacteriophage can be developed given the constraints of the commercial poultry production system. Environmental augmentation with bacteriophage, where bacteriophages are introduced into the environment to reduce the infectious dose of a targeted pathogen, may prove to be practical and effective. Smith et al. (1987) found that treating the bedding of calf stalls was very effective in preventing E. coli induced diarrhea; in fact, this application was even more efficacious than oral administration of bacteriophage. Recently, Oliveira et al. (2010) demonstrated that morbidity and mortality in commercial poultry facilities from colibacillosis could be reduced by spraying facilities with bacteriophage and administration of bacteriophage in the drinking water. The etiology of colibacillosis makes it difficult to treat with bacteriophage therapy, where a respiratory infection rapidly becomes a systemic infection. However, enteric diseases may be more susceptible to bacteriophage therapy. Miller et al. (2010) demonstrated efficacy of bacteriophage to prevent and treat necrotic enteritis with the practical application of bacteriophages in ovo, and in both the feed and water.
The current research demonstrates both the potential and limitations of the development of bacteriophage therapeutics for the poultry industry. For bacteriophage therapeutics to be effective, they must deliver sufficient titers of bacteriophage to the site of a bacterial infection. Further research on the development of bacteriophage therapeutics for applications in the poultry industry is needed because they do offer a natural and safe alternative to antibiotics. Augmentation of poultry production and hatchery facilities with bacteriophage could reduce the load of both pathogenic and foodborne bacteria. Encapsulation of bacteriophage for oral administration could possibly allow the translocation of bacteriophage from the intestinal tract, providing systemic therapeutic titers of bacteriophage. In ovo administration of bacteriophage could also provide a practical and efficacious method to protect the chick from pathogenic bacteria as well as preventing colonization with foodborne pathogens. The effects of these treatments on mortality at 21 d of age. The treatments were 1) not treated and not challenged control; 2) birds treated with a fine spray of bacteriophage and not challenged; 3) birds administered intratracheal (IT) bacteriophage and not challenged; 4) birds not treated and challenged with Escherichia coli; 5) birds treated with a fine spray of bacteriophage and IT challenged with E. coli; and 6) birds treated IT with bacteriophage and challenged IT with E. coli. The values represent the means of 3 replicate pens of 10 birds per pen at each treatment, and the letters (a,b) indicate significant differences between treatment means (P ≤ 0.05).
